Farallon Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Farallon Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,160,000	Closed	-$87.3M	–	324
2022 Q2	$87.3M	Buy	+1,160,000	New	+$51.6M	0.47%	59
2021 Q3	–	Sell	-465,000	Closed	-$36.3M	–	321
2021 Q2	$36.3M	Sell	465,000 -35,000	-7%	-$2.59M	0.15%	84
2021 Q1	$47.3M	Buy	+500,000	New	+$59.5M	0.24%	75

Farallon Capital Management's TPTX Position: Q3 2022 in Review

Farallon Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 1,160,000 shares — an estimated $87.3M sold.

Farallon Capital Management first reported a position in TPTX in Q1 2021 and held it in 3 quarters. The position peaked at $87.3M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Farallon Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Farallon Capital Management sold 1,160,000 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $87.3M.
Farallon Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
Farallon Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $87.3M in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Farallon Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.